IGF-1 LR3

Also known as: Long R3 IGF-1

Limited evidence
ClassInsulin-like growth factor analog
Research statusResearch use only
Independent tests1
Studies indexed3
Companies tested 1

Overview

A modified IGF-1 analog with reduced binding-protein affinity and a substantially extended half-life.

IGF-1 LR3 is classified as an insulin-like growth factor analog. Its current development status is: research use only. The published evidence is thin, largely non-independent, or does not address the uses this compound is marketed for.

The Peptide Institute tracks IGF-1 LR3 because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.

Independent Testing

Independently tested companies that sell IGF-1 LR3

Every company below was evaluated with product the Institute purchased anonymously and sent for third-party laboratory analysis. Ranked by Index Score™.

Companies
1
Samples
1
Updated
Dec 29, 2024
  1. 1 Lumen Research Supply Excellent Institute
    Top Rated     IGF-1 LR3

    98.7% average purity across 1 sample

    Purity & Testing 99 Transparency 80 Samples 1 89 View company
See the full testing database

Research & Studies

Studies library

  • Mechanistic characterization of IGF-1 LR3 receptor binding

    Journal of Clinical Endocrinology & Metabolism · Systematic review · Dec 8, 2022

    One of the more methodologically careful entries in the IGF-1 LR3 literature.

  • Long-term outcomes with IGF-1 LR3: an open-label extension

    Peptides · Randomized controlled trial (Phase 3) · May 1, 2014

    Reports findings relevant to the primary claims made for IGF-1 LR3; sample size limits how far the result generalises.

  • Long-term outcomes with IGF-1 LR3: an open-label extension

    Obesity · Pharmacokinetic study (Phase 1) · Aug 28, 2013

    Characterises IGF-1 LR3 activity in a controlled setting. Endpoints are surrogate measures rather than clinical outcomes.

Independent Testing

Testing database

Laboratory verification of IGF-1 LR3 products across the companies we index.

IGF-1 LR3 Lumen Research Supply
Purity 98.7% Verified

Community Discussions

Forum

The Peptide Institute Weekly

Research. Testing. Regulation. No hype.

One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.

  • New research, summarized in plain English
  • Independent lab results as they publish
  • Score and ranking movements